Thor Medical (TRMED.OL) Stock Analysis & AI Equity Report

Biotechnology NOK Explore free reports

Thor Medical (TRMED.OL) overview

Thor Medical (TRMED.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, Thor Medical reported revenue of NOK 0.4m and operating profit of NOK -69.7m; the year-end share price was 5.25 NOK and market capitalisation was NOK 1,743m. Thor Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Thor Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueNOK 456mFY 2025
Share price5.25 NOKFY 2025 year end
RevenueNOK 0.4mFY 2025
Operating profitNOK -69.7mFY 2025
Net earningsNOK -58.0mFY 2025
Market capitalisationNOK 1,743mFY 2025 year end

Figures updated on 2026-07-28. Data will be refreshed during report generation.

About Thor Medical

Thor Medical ASA develops and supplies alpha-particle emitters for radiopharmaceutical companies working on targeted cancer therapies. The company uses a proprietary production process based on naturally occurring thorium, without nuclear reactors or irradiation, to produce high-purity isotopes. It operates pilot-scale production in Norway and is developing larger-scale capacity for commercial deliveries.

Generate the Thor Medical report

Thor Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Thor Medical and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Thor Medical

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.